Home › Funds › SEGALL BRYANT & HAMILL, LLC › HALO
SEGALL BRYANT & HAMILL, LLC position in HALO
HALOZYME THERAPEUTICS INC · Health Care
SEGALL BRYANT & HAMILL, LLC reported holding 313,010 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$34.6M, representing 0.46% of its reported portfolio and ranking #49 among its reported holdings. SEGALL BRYANT & HAMILL, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How SEGALL BRYANT & HAMILL, LLC's HALO position evolved
SEGALL BRYANT & HAMILL, LLC first disclosed a stake in HALO in Q3 2023 at 218,405 shares (US$8.3M). The position peaked in Q3 2026 at 313,010 shares, worth US$34.6M. Across 13 filings, SEGALL BRYANT & HAMILL, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 313,010 shares valued at US$34.6M — a reduction of -4,914 shares quarter over quarter.. Notable position changes include a 30% trim in Q3 2025 (shares fell 8% over the following quarter), a 42% increase in Q4 2025 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 218.41K | $8.34M | New |
| Q4 2023 | 242.47K | $8.96M | Add |
| Q1 2024 | 269.96K | $10.98M | Add |
| Q2 2024 | 305.32K | $15.99M | Add |
| Q3 2024 | 355.18K | $20.33M | Add |
| Q4 2024 | 353.10K | $16.88M | Reduce |
| Q1 2025 | 343.17K | $21.90M | Reduce |
| Q2 2025 | 310.83K | $16.17M | Reduce |
| Q3 2025 | 216.57K | $15.88M | Reduce |
| Q4 2025 | 307.22K | $20.68M | Add |
| Q1 2026 | 298.06K | $19.26M | Reduce |
| Q2 2026 | 317.92K | $24.88M | Add |
| Q3 2026 | 313.01K | $34.56M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$244.3M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- SNYDER CAPITAL MANAGEMENT L P 2.21M sh · $244.28M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.62M sh · $178.46M · Q3 2026
- FULLER & THALER ASSET MANAGEMENT, INC. 1.60M sh · $176.98M · Q3 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.58M sh · $174.27M · Q3 2026
- Stephens Investment Management Group LLC 1.41M sh · $156.00M · Q3 2026
- GW&K Investment Management, LLC 1.14M sh · $125.86M · Q3 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Boston Trust Walden Corp 1.04M sh · $114.35M · Q3 2026
- LMR Partners LLP 45.00M sh · $65.81M · Q2 2026
More on SEGALL BRYANT & HAMILL, LLC
FAQ
How long has SEGALL BRYANT & HAMILL, LLC held HALO?
SEGALL BRYANT & HAMILL, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SEGALL BRYANT & HAMILL, LLC's current position in HALO?
As of Q3 2026, SEGALL BRYANT & HAMILL, LLC holds 313.01K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $34.56M, representing 0.46% of its reported portfolio and ranking #49.
Has SEGALL BRYANT & HAMILL, LLC been buying or selling HALO?
In the latest 13F filing (Q3 2026), SEGALL BRYANT & HAMILL, LLC reduced its position in HALO. The position peaked in Q3 2026 at 313.01K shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.